Meridian Radiopharmaceuticals is on a mission to transform bone metastases from a terminal diagnosis into a curable condition.
We are pioneering a targeted radiotherapy that not only relieves symptoms but eradicates cancer in the bones, giving patients renewed hope for a future beyond metastatic cancer.
Sales Overview
+26%
2.600.000
Familiar Elements, Novel Fusion
We harness a powerful fusion of biology and physics to fight cancer. Meridian’s approach links bone-seeking, FDA-approved bisphosphonates with Polonium-210, a potent alpha-emitting isotope. This means we can deliver intense, tumor-killing radiation straight to cancer cells in bone – maximizing impact on tumors while minimizing harm to healthy tissue.
Development Pipeline
Our pipeline is centered on treating metastatic cancer in the bone — one of oncology’s most painful and underserved areas. We are evaluating multiple drug candidates for use across breast, prostate, lung, and other cancers.
Contact Us
We invite you to connect with Meridian. Whether you’re an investor, a potential partner, or a healthcare advocate, we’re eager to discuss our work and opportunities for collaboration. Reach out to learn how you can be part of our journey to cure bone metastases.
